Belvedere Trading
CTMX icon

Belvedere Trading’s CytomX Therapeutics CTMX Stock Holding History

Belvedere Trading’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-24,200
Closed -$38.7K – 1034
2022
Q4 		$38.7K Buy
+24,200
New +$35.8K ﹤0.01% 703

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Belvedere Trading's CTMX Position: Q1 2023 in Review

Belvedere Trading sold out of CytomX Therapeutics (CTMX) in Q1 2023, closing a stake of 24,200 shares — an estimated $38.7K sold.

Belvedere Trading first reported a position in CTMX in Q4 2022 and held it in 1 quarter. The position peaked at $38.7K in Q4 2022. 75 funds tracked by Wall St. Rank hold CTMX as of Q1 2023.

  • Belvedere Trading reported no remaining CytomX Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Belvedere Trading sold 24,200 CytomX Therapeutics shares in Q1 2023, an estimated $38.7K.
  • Belvedere Trading first reported a position in CytomX Therapeutics in Q4 2022 and held it in 1 quarter.
  • Belvedere Trading's CytomX Therapeutics position peaked at $38.7K in Q4 2022.
  • 75 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2023.

Based on Belvedere Trading's 13F filing for Q1 2023, filed 15 May 2023.